amyotrophic
- بهمن- 1396 -19 بهمن
Gilead and Sangamo deal shows that CRISPR still has competition
Gilead and Sangamo deal shows that CRISPR still has competition Gilead Sciences is betting big on gene editing to bolster its cell-based immunotherapy division, but…
-- بیشتر بخوانید -- - دی- 1396 -22 دیدیگر
Good cells gone bad
The leader of the study, TSRI Professor Stuart Lipton, M.D., Ph.D., is now investigating how new pharmaceuticals might counteract this harmful S-nitrosylation reaction. “The new…
-- بیشتر بخوانید --
